title: Prostacyclin and thromboxane levels in women with severe preeclampsia undergoing magnesium sulfate therapy during antepartum and postpartum periods.
abstract: OBJECTIVE
  To study effects of magnesium sulfate (MgSO(4)) on prostacyclin (PGI(2)) and thromboxane A(2) (TXA(2)) levels in women with severe preeclampsia during antepartum and postpartum periods.
  
  
  METHODS
  Women with severe preeclampsia were randomized into two groups. Patients in Group A were continuously infused with MgSO(4) for 24 hours postpartum. In Group B, MgSO(4) administration was discontinued when urinary output was of > or =100 ml/hr for 2 consecutive hours. Patient demographic data were collected. Venous blood was drawn at time of MgSO(4) administration and 24 hours after delivery. Plasma levels of 6-keto-PGF1alpha and TXB(2), stable metabolites of PGI(2) and TXA(2), were measured by enzyme-linked immunosorbent assay (ELISA). Data are presented as mean +/- SE, and analyzed by paired t-test.
  
  
  RESULTS
  A total of 50 patients were recruited, with 27 in Group A and 23 in Group B. There were no statistical differences for demographic data between the two groups with regards to maternal age; gestational age; systolic and diastolic blood pressures at admission, 12 hours postpartum, and 24 hours postpartum; and mode of delivery. Platelet counts were all within the normal range at the time of enrollment. MgSO(4) was administered for an average of 10 hours postpartum in Group B. Maternal blood pressures returned to normal or close to normal levels in both groups at 24 hours postpartum. 6-keto PGF1alpha levels were significantly decreased 24 hours after delivery compared with the levels at enrollment in both groups, (Group A: 98 +/- 13 vs. 180 +/- 28 pg/mL; Group B: 142 + 17 vs. 194 +/- 31 pg/mL, p < 0.05, respectively). However, there was no difference detected between the two groups. TXB(2) levels were not different between group A and Group B at the time of enrollment, 38 +/- 9 vs. 33 +/- 8 pg/mL, and 24 hours postpartum, 26 +/- 5 vs. 25 +/- 3 pg/mL, respectively.
  
  
  CONCLUSIONS
  Administration of MgSO(4) does not affect prostacyclin and thromboxane levels in the maternal circulation in women with preeclampsia during antepartum and postpartum periods. We speculate that a higher level of prostacyclin before delivery may reflect compensatory effects of this vasodilator to offset increased maternal blood pressure during pregnancy.
authors.affiliation: Department of Obstetrics and Gynecology, Louisiana State University Health Sciences Center, Shreveport, LA 70030, USA. ywang1@lsuhsc.edu
authors.forename: Yuping
authors.initials: Y
authors.lastname: Wang
authors.forename: Yanping
authors.initials: Y
authors.lastname: Zhang
authors.forename: Bernard J
authors.initials: BJ
authors.lastname: Canzoneri
authors.forename: Yang
authors.initials: Y
authors.lastname: Gu
authors.forename: Lisa
authors.initials: L
authors.lastname: Philibert
authors.forename: David F
authors.initials: DF
authors.lastname: Lewis
mesh_terms: D000293:Adolescent; D000328:Adult; D004797:Enzyme-Linked Immunosorbent Assay; D011464:Epoprostenol / Q000097:blood*; D005260:Female; D006801:Humans; D008278:Magnesium Sulfate / Q000627:therapeutic use; D049590:Postpartum Period / Q000097:blood*; D011225:Pre-Eclampsia / Q000097:blood* / Q000188:drug therapy*; D011247:Pregnancy; D012720:Severity of Illness Index; D013928:Thromboxane A2 / Q000097:blood*; D015149:Tocolytic Agents / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D015149:Tocolytic Agents; D013928:Thromboxane A2; D008278:Magnesium Sulfate; D011464:Epoprostenol